Fellowship · Chicago, IL
Sponsored by Chicago Medical School/Rosalind Franklin University of Medicine & Science
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · 202 citations · Celalettin Ustun
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal.
HemaSphere · 2021 · 257 citations · Celalettin Ustun
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.
Blood · 2025 · 52 citations · Celalettin Ustun
Avapritinib versus Placebo in Indolent Systemic Mastocytosis.
NEJM evidence · 2023 · 73 citations · Celalettin Ustun
Systemic mastocytosis: current status and challenges in 2024.
Blood advances · 2025 · 22 citations · Celalettin Ustun
Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice.
The journal of allergy and clinical immunology. In practice · 2022 · 61 citations · Celalettin Ustun
Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors.
JAMA oncology · 2022 · 73 citations · Celalettin Ustun
Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy.
Haematologica · 2025 · 19 citations · Celalettin Ustun